The tyrosine kinase inhibitor Dasatinib blocks in-vitro HIV-1 production by primary CD4+ T cells from HIV-1 infected patients

Pogliaghi, Manuelaa,b,c; Papagno, Lauraa,b,d; Lambert, Sidoniee,f,g; Calin, Ruxandrae,f,h; Calvez, Vincente,f,g; Katlama, Christinee,f,h; Autran, Brigittea,b

AIDS:
doi: 10.1097/QAD.0000000000000073
Research Letters
Abstract

HIV reservoirs persistence despite antiretroviral therapy (ART) might be related to persistent immune activation and residual HIV production, requiring further therapeutic strategies. We demonstrated that the tyrosine kinase inhibitor (TKI) Dasatinib, used for chronic myeloid leukaemia, significantly blocks in vitro HIV1 production by 3.4 logs in HIV1-infected primary CD4+ T lymphocytes, by inhibiting cell activation and proliferation, without cell toxicity. This molecule deserves to be investigated further for HIV cure strategies to hinder persistent immune activation and residual viral production.

Author Information

aUPMC Univ Paris 06, UMR-S945

bInserm, U945, Laboratory of Immunity and Infection, Paris, France

cUniversità Vita-Salute, San Raffaele Scientific Institute, Milan, Italy

dORVACS, Hospital Pitié-Salpêtrière

eUPMC Univ Paris 06, UMR-S943, Epidemiology, Therapeutics Strategies and Clinical Virology in HIV Infection, Paris, France

fInserm, U943, Epidemiology, Therapeutics Strategies and Clinical Virology in HIV Infection

gAP-HP, Hospital Pitié-Salpêtrière Hospital, Department of Virology

hAP-HP, Hospital Pitié-Salpêtrière Hospital, Department of Infectious and Tropical Diseases, Paris, France.

Correspondence to Brigitte Autran, Hôpital Pitie-Salpêtriere, Département d’immunologie, Paris, France. Tel: +33 142177930; fax: +33 142177490; e-mail: brigitte.autran@psl.aphp.fr

© 2014 Lippincott Williams & Wilkins, Inc.